CURATIVE BIOTECHNLOGY NEW (CUBTD) Stock News

Curative Biotechnology (CUBT, temporarily CUBTD) executed a 1-for-150 reverse stock split effective March 23, 2026, reducing outstanding shares from ~1.02 billion to ~6.8 million and DTC-eligible shares from ~266.8 million to ~1.78 million. The company's ticker will show as CUBTD for 20 trading days.

Curative plans manufacturing to begin mid-April 2026, received a U.S. manufacturer proposal for sterile metformin ophthalmic drops, intends a Phase 1 NIH CRADA human study for dry AMD, and will pursue an OTCQB uplisting after a manufacturing agreement.